DEPLOYDatabase

Deployment

Versius at United States

CMR Surgical (founded 2014, Cambridge, UK; private) makes Versius, the genuine challenger among surgical-robot startups and the one that has clearly crossed the regulatory gating event. Versius is a modular multi-arm teleoperated soft-tissue robot that is heavily software-driven, capturing telematic, video, and outcome data. It received US FDA De Novo marketing authorization in October 2024, the first such authorization for a multi-port soft-tissue general-surgery robot, followed by an FDA 510(k) clearance for the next-generation Versius Plus on December 18, 2025 with US commercialization on track for 2026, and a pending gynecology 510(k) submitted on April 29, 2026; it has long been CE-marked and commercial across Europe, Latin America, the Africa-Middle-East region, and Australia, with more than 40,000 procedures completed outside the US by company reporting.

The registry records it at commercial maturity with an active lifecycle. An important current-state correction: the 2021 roughly $3 billion SoftBank-led valuation story is frozen in time, the company went through real restructuring in 2023 with about 350 redundancies, and it was recapitalized with more than $200 million in April 2025, while reported figures of a roughly $3.1 billion 2025 valuation and a potential $4 billion sale are rumor-tier aggregator claims that are not registered.

On AI substance the shipped reality is a data-capture and analytics ecosystem with the surgeon in full control; the physical-AI framing is forward-looking, anchored in a March 2026 NVIDIA IGX Thor partnership to evaluate AI for a future Versius, with no autonomous or AI-assisted intraoperative feature cleared or shipped.

Versius by CMR Surgical · Catalog entry · 1 source · not yet field-verified · Surgical robots

Recent coverage

See all coverage →


CMR Surgical said in December 2025 that it received FDA 510(k) clearance for Versius Plus for gallbladder removal, and that it was on track to begin launching the system in the U.S. in 2026. The robot is modular, so it can be moved between operating rooms.

Key facts

FDA clearance
Dec 2025 (Versius Plus)
US launch
Planned for 2026

Safety record

No incidents on record for Versius at United States.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Trust tier
Catalog entry · 1 source · not yet field-verifiedhow tiers work →
Last updated
2026-11-01
Model
Versius
Operator
CMR Surgical
Status
announced
First seen
2025-12-01
ID
e6d82d75-839b-431e-9edc-649379ddb6e8

Timeline

  1. Dec 2025
    First recorded
    Versius first documented operating at United States.
  2. Nov 2026
    Current status: announced, reviewed
    Latest recorded state. New status transitions append here as the deployment-status recorder produces them.

On the deployment map

Operates worldwide

Versius is deployed globally rather than at a single verified site, so there is no map pin.

Free to use on your site, with a link back to DEPLOY.

Versius operates in United States. Explore the full verified map:

Sources (1)

  1. https://www.medtechdive.com/news/CMR-Surgical-FDA-clearance-Versius-Plus-robot/808140/ · 2025-12-01
Methodology: Verified · 1 source (no primary) · last reviewed 2026-11-01

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-11-01

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

1
secondary-trade-publication
Trade publication

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Versius at United States.

Common questions

What is the Versius deployment at United States?
Versius, built by CMR Surgical, is recorded as a deployment at United States on the DEPLOY registry. CMR Surgical operates the deployment directly.
Who operates Versius at United States?
CMR Surgical, the manufacturer of Versius, operates this deployment directly. This is a maker-deploys-its-own-product arrangement rather than a customer pilot.
When did the Versius deployment at United States go live?
The deployment is recorded as starting December 1, 2025 on the DEPLOY registry. Earlier activity may exist but is not yet sourced.
Is the Versius deployment at United States still active?
As of the most recent verification on the DEPLOY registry, this deployment is announced but not yet operating.
Have there been incidents at the Versius deployment at United States?
No active incidents affecting this deployment are recorded on the DEPLOY registry. Absence of recorded incidents is not a guarantee no incident occurred; DEPLOY records only sourced incidents and suppresses retracted ones.

Deploy Watch

Track this deployment.

We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.

Machine-readable surfaces